The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 65.00
Bid: 64.00
Ask: 66.00
Change: 1.00 (1.56%)
Spread: 2.00 (3.125%)
Open: 64.00
High: 65.50
Low: 64.00
Prev. Close: 64.00
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

22 Jul 2015 07:00

RNS Number : 7065T
MyCelx Technologies Corporation
22 July 2015
 

MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)

Half Year Trading Update

MYCELX Technologies Corporation (AIM: MYX), the clean water technology company providing patented solutions for commercial industrial markets worldwide, announces a trading update ahead of its 2015 Half Year Results which will be released on 10 September 2015.

 

Trading conditions over the first half of 2015 continued to be challenging for the oil and gas industry and the associated service sector, with many of the operators exercising stringent capital discipline. In the face of the difficult market, MYCELX notes the resilience of its business sales which amounted to $8.6m in H1 compared to $7.5m in the same period last year. The increase demonstrates that our technology continues to deliver value in an industry that is struggling with significant price dislocation and is consequently focused on extreme cost reduction measures. These market conditions are expected to continue throughout the second half of the year.

Leveraging the success of two petrochemical plant turnarounds in H1, the Company is aggressively pursuing this market in H2 and beyond, given our technology and expertise has proven to be very effective in this application. The budgets and schedules for these projects are already approved eliminating uncertain and protracted timelines. Additionally, the Company is taking advantage of the departure of several oil field services companies that were providing water management for US onshore production by actively pursuing projects where previous treatment options are no longer economically viable. The Company has entered into strategic agreements which it believes will accelerate this fast-to-market opportunity.

Given the adverse market conditions which have resulted in cancellations and delays in capital approvals for major projects across the industry, MYCELX is updating its guidance on FY 2015 outlook. The Company notes that were there to be no new contract wins and based on the current run rate, it expects total revenue would be in the range of $15 - 16.5 million, representing a 10-20% improvement on FY2014. The Company regrets that at this time one of the major projects that it was previously pursuing has not progressed further and its timetable is now unclear. MYCELX continues to progress the larger of the major projects in its near term pipeline, where the operator has paid for additional trials to further refine their overall clean water solution. Furthermore, MYCELX is pursuing additional opportunities, most notably for Enhanced Oil Recovery (EOR) applications, where the Company's technology has proven to be uniquely capable. The effect of capital approval delays has pushed an increasing proportion of the revenue from actively pursued projects out into H2 2015 and beyond. The Company also notes that its cost reduction programme is now well progressed and on track to deliver 10% savings for the full year.

For further information please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO Tel: +1 888 306 6843

Mark Clark, CFO

 

RFC Ambrian Limited Tel: +44 20 3440 6800

Corporate Finance

Samantha Harrison

Alexander Millar

 

Corporate Broking

Jonathan Williams

Kim Eckhof

 

Numis Securities Limited Tel: +44 20 7260 1000

Corporate Broking

James Black

Ben Stoop

 

Bell Pottinger Tel: +44 20 3772 2500

Nick Lambert

Henry Lerwill

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFLLBLEDFZBBK
Date   Source Headline
5th Nov 20217:00 amRNSDirector/PDMR Shareholding
28th Oct 20214:34 pmRNSHolding(s) in Company
14th Oct 20217:00 amRNSMiddle East Contract Win
29th Sep 20217:00 amRNSHalf Year Results Statement
31st Aug 20217:00 amRNSNotice of Interim Results & Investor Presentation
11th Aug 20217:00 amRNSHolding(s) in Company
4th Aug 20217:00 amRNSContract Award and Contract Extension
7th Jul 20215:41 pmRNSResult of AGM
4th Jun 20218:00 amRNSMailing of Annual Financial Report and AM Notice
26th May 20217:00 amRNSFinal Results for the year ending 31 December 2020
19th May 20217:00 amRNSInvestor Presentation
14th May 20217:00 amRNSPFAS System Validation
13th Apr 20211:49 pmRNSGrant of Options
23rd Mar 20217:00 amRNSBoard Changes
17th Mar 20213:37 pmRNSHolding(s) in Company
17th Mar 20212:35 pmRNSHolding(s) in Company
15th Mar 20217:00 amRNSHolding(s) in Company
2nd Mar 20217:00 amRNSTrading Update
18th Feb 20217:00 amRNSSale of MYCELX property in Duluth, USA
17th Feb 20214:32 pmRNSHolding(s) in Company
5th Jan 20212:32 pmRNSHolding(s) in Company
4th Jan 20217:00 amRNSHolding(s) in Company
27th Oct 20202:55 pmRNSResult of Annual Meeting
2nd Oct 20202:56 pmRNSNotice of Annual Meeting
22nd Sep 20207:00 amRNSHalf Year Results Statement
4th Sep 20207:00 amRNSAppointment of Nominated Adviser and Sole Broker
7th Aug 202011:50 amRNSDirector/PDMR Shareholding
22nd Jun 20207:00 amRNSContract extension with SABIC
19th Jun 20207:00 amRNSAnnual Financial Report
27th May 20207:00 amRNSFinal Results for the year ending 31 December 2019
11th May 20207:00 amRNSNew Project Award
14th Apr 20207:00 amRNSTrading Update
9th Mar 20207:00 amRNSClosure of Restricted Stock Line
5th Mar 20207:00 amRNSTrading Update
13th Dec 201910:25 amRNSBlock listing Interim Review
4th Nov 20197:00 amRNSTrading Update
16th Sep 20197:00 amRNSHalf Year Results Statement
20th Aug 201912:42 pmRNSHolding(s) in Company
16th Aug 20193:02 pmRNSDirector Shareholding
29th Jul 20197:00 amRNSDirectorate Changes
26th Jul 20197:00 amRNSAppointment of Nominated Adviser & Broker
22nd Jul 20191:34 pmRNSHolding(s) in Company
10th Jul 201912:57 pmRNSResult of Annual Meeting
14th Jun 20197:00 amRNSTrading Update
11th Jun 20197:00 amRNSBlock listing Interim Review
6th Jun 20197:00 amRNSIssue of Equity
31st May 20191:57 pmRNSAnnual Financial Report
13th May 20197:00 amRNSFinal Results for the year ending 31 December 2018
28th Mar 20197:00 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.